This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Humana, Viatris, agilon health and Cano Health
by Zacks Equity Research
Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.
Zacks.com featured highlights Marcus, AssetMark Financial, Humana, Riely Exploration Permian and ICF International
by Zacks Equity Research
Marcus, AssetMark Financial, Humana, Riely Exploration Permian and ICF International have been highlighted in this Screen of The Week article.
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued strength in its Global Industrial segment.
4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates
by Kaibalya Pravo Dey
Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).
Buy These 5 Low Leverage Stocks Ahead of Big Earnings Releases
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt as a debt-free stock is almost impossible to find. You may buy MCS, AMK, HUM, REPX and ICFI.
Is a Surprise Coming for Humana (HUM) This Earnings Season?
by Zacks Equity Research
Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Humana's (HUM) Q1 Earnings Beat on Insurance Unit Strength?
by Zacks Equity Research
Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.
What's in Store for Molina Healthcare (MOH) in Q1 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $491.21, moving +0.18% from the previous trading session.
Universal Health (UHS) to Release Q1 Earnings: Factors to Note
by Zacks Equity Research
Universal Health's (UHS) Q1 results are likely to benefit from higher patient volumes and solid demand for behavioral healthcare services. However, increased labor costs might partly offset the results.
Humana (HUM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Humana (HUM) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $518.82 in the latest trading session, marking a -0.96% move from the prior day.
UnitedHealth (UNH) Buys Crystal Run to Boost Value-Based Care
by Zacks Equity Research
UnitedHealth Group (UNH) acquires Crystal Run, as per multiple reports. The move tends to offer enhanced value-based care across the Hudson Valley and lower Catskill region.
Wall Street Bulls Look Optimistic About Humana (HUM): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Humana (HUM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Humana (HUM) Is Up 7.11% in One Week: What You Should Know
by Zacks Equity Research
Does Humana (HUM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com featured highlights include Marcus, GameStop, AssetMark Financial, Humana and ICF International
by Zacks Equity Research
Marcus, GameStop, AssetMark Financial, Humana and ICF International are part of the Zacks Screen of the Week article.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $524.56, marking a +0.88% move from the previous day.
Are Medical Stocks Lagging Humana (HUM) This Year?
by Zacks Equity Research
Here is how Humana (HUM) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Buy These 5 Low Leverage Stocks as U.S. Releases Job Report
by Aparajita Dutta
Investors seem to be encouraged by the March jobs report, which reflects a resilient economy and moderate inflation. You may buy MCS, GME, AMK, HUM & ICFI.
Will Humana (HUM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Diverse Medical Stocks to Buy for 2023 and Beyond
by Shaun Pruitt
The top and bottom-line growth make these Zacks Medical stocks very attractive.
Humana (HUM) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Humana (HUM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
If You Invested $1000 in Humana a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.